1results about How to "Effective immune response" patented technology

This invention discloses a porcine reproductive and respiratory syndrome virus (PRRSV) mRNA molecule and its applications. Four mRNA vaccines, GP35m-LNP, GP45m-LNP, GP345m-LNP, and GP2345m-LNP, were designed by combining the NADC30-like structural proteins GP2a, GP3, GP4, and GP5 of the PRRSV FJ1402 strain. Mouse experiments showed that GP345m-LNP induced both strong humoral and cellular immune responses, followed by GP2345m-LNP, with better efficacy than the inactivated vaccine (which only induced humoral immunity). After immunization, challenge with the PRRSV FJ1402 strain resulted in significantly reduced viral load in the blood and lungs of the GP345m-LNP group, with significantly less pathological damage to the lungs. The immunization effect was superior to the inactivated vaccine group, demonstrating promising application prospects.